System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Hans-Christian Kolberg is an expert in Oncology at Marienhospital Bottrop (Germany). As of October 2026, ScienceLeadR ranks Hans-Christian Kolberg in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Hans-Christian Kolberg has authored 289 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 19 of them ongoing. SLR score: 1,328 (community average: 125). How the SLR is computed.

LeadR Profile

Hans-Christian Kolberg Marienhospital Bottrop Germany
1 328 ScienceLeadR Reputation 1328

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Radiotherapy - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Marienhospital Bottrop

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 289

Citations

Citations: 4 815 1st author: 71 Last author: 26 Unique author: 2

Main journals

Geburtshilfe Frauenheilkd 63
Senologie - Zeitschrift für Mammadiagnostik und -therapie 53
Cancer Res 35
J Clin Oncol 23
Breast Care (Basel) 10

Best Journals

J Clin Oncol 15
N Engl J Med 3
Ann Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Incidence Rates of Adverse Events (CTCAE Severity ≥3) During HER2-Directed Breast Cancer Treatment Assessing the Impact of App-Based Electronic Patient-Reported Outcomes in the Randomized Controlled PRO2 Trial.
PMID 42930185 — hospitalization, breast neoplasms, incidence, neoplasms, drug-related side effects and adverse reactions, odds ratio, breast, patient reported outcome measures, therapeutics		Curr Oncol20260
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.
PMID 41965791 — registries, poly(adp-ribose) polymerase inhibitors, breast neoplasms, neoplasms, breast, therapeutics, mutation		NPJ Breast Cancer20260
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.
PMID 41925922 — fulvestrant, breast neoplasms, neoplasms, hormones, breast, therapeutics, mutation		Breast Cancer Res Treat20260
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study.
PMID 41564379 — lymph nodes, breast neoplasms, neoplasms, seeds, lymph, breast, neoadjuvant therapy, radar, therapeutics		J Clin Oncol Top journal20262
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
PMID 41564397 — triple negative breast neoplasms, breast neoplasms, progression-free survival, neoplasms, drug therapy, breast, chemotherapy		N Engl J Med Top journal20267

Clinical Studies 29

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 3 16
N/A 5
Phase 2 4
Phase 4 4

By status:

Recruiting 14
Active not recruiting 5
Completed 4
Not yet recruiting 3
Terminated 2
Unknown 1

By type:

Interventional 26
Observational 3

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 1
multicentricup10 23

Main Topics

Ongoing Clinical Trials

19 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase Ib III Study of Capivasertib CDK4 6 Inhibitors Fulvestrant as Treatment for Advanced Metastatic HR HER2 Breast Cancer (CAPItello 292)
2023-504997-39-00 — genes, epidermal growth factor, fulvestrant, growth, breast neoplasms, neoplasms, hormones, receptors, growth factor, breast, therapeutics		Phase 3Active not recruiting2021
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician s Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer
2023-506821-12-00 — estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, everolimus, breast, therapeutics		Phase 3Active not recruiting2023
HER2DX guided diagnostic treatment For patients with HER2 positive early stage breast cancer
2025-521040-37-00 — quality of life, breast neoplasms, neoplasms, breast, therapeutics		Phase 3Not yet recruiting2025
Patient Centered Study of T DXd in Metastatic HER2 Positive Breast Cancer with Real Life Side Effect Management
2025-521805-41-00 — quality of life, breast neoplasms, neoplasms, drug therapy, breast, therapeutics, trastuzumab, chemotherapy		Phase 3Not yet recruiting2026
Adjuvant Dynamic marker Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and or clinically high risk ER HER2 early breast cancer (ADAPTela)
2025-522484-15-00 — breast neoplasms, neoplasms, breast, therapeutics		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS